Inactive ingredients, such as peanut oil in an adjuvant or vaccine carrier, does not have to appear on the label of a vaccine.

Date:   1/18/2009 3:26:19 PM ( 15 y ago)

The biggest objection I have come across to my hypothesis which is now "Vaccines are the major cause of food allergy" is that we have laws so the vaccine manufacturers have to list all of the ingredients on the package insert. Ding, dong, you're wrong!! Food has to be labeled. Medicines are not food. Active ingredients appear on the labels - "inactive" ingredients don't have to....

http://www.vran.org/vaccines/anaphylaxis/vaccine-ana.htm What is being injected into our children? Why can't we find out? What adjuvants are used in the vaccines? An Access to Information request to Health Canada for the 100% composition of vaccines given to infants received the response, "I regret to inform you that the exact composition of these vaccines cannot be disclosed to you as the information is protected under ATIA (Access to Information Act) Section 20(1)(a)(b)(c). This is a mandatory exemption which protects confidential business information." The Act, under Third Party Information, states, 20. (1) Subject to this section, the head of a government institution shall refuse to disclose any record requested under this Act that contains a) trade secrets of a third party; b) financial, commercial, scientific or technical information that is confidential information supplied to a government institution by a third party and is treated consistently in a confidential manner by the third party; c) information the disclosure of which could reasonably be expected to result in material financial loss or gain to, or could reasonably be expected to prejudice the competitive position of, a third party; or d) information the disclosure of which could reasonably be expected to interfere with contractual or other negotiations of a third party."

http://www.aphis.usda.gov/animal_health/vet_biologics/publications/memo_800_51.pdf VETERINARY SERVICES MEMORANDUM NO. 800.51 It is understood that in some cases, adjuvants are purchased from another firm and therefore some of the data listed may be the proprietary information of the supplier and may not be available to an applicant buying the materials from that source. In this case, it is acceptable for the applicant to arrange to have the adjuvant supplier submit adjuvant information to the CVB, in a manner that protects confidential business information.

http://www.techagreements.com/agreement-preview.aspx?num=616974&title=Avant%20Immunotherapeutics%20-%20Collaboration%20And%20License%20Agreement VLP. Drug delivery vehicles, adjuvants, and excipients shall not be deemed to be "active ingredients", except in the case where such delivery vehicle, adjuvant, or excipient is recognized as an active ingredient in accordance with 21 C.F.R. 210.3(b)(7).

http://www.123jump.com/10K_Reports/ANDS/2005/2005.htm Intellectual Property and Patents           Our policy is to pursue patents and to otherwise endeavor to protect our technology, inventions and improvements that are commercially important to the development of our business. We also rely upon trade secrets that may be important to the development of our business.           Our success will depend in large part on our ability to:     •   obtain and maintain patent and other proprietary protection for the technology, inventions and improvements we consider important to our business;       •   defend our patents;       •   preserve the confidentiality of our trade secrets; and ...We also rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable.

http://www.patentstorm.us/patents/6398774/description.html Exhibit D, Trade Secret/Confidential Information--(enclosed separately)

http://query.nytimes.com/gst/fullpage.html?sec=health&res=9a00e2d8153ff934a15754c0a9609c8b63 The nature of GlaxoSmithKline's adjuvant is a trade secret, but David Stout, president for worldwide pharmaceuticals at the company, said the ingredients had already been given to people in other products, though not in this particular combination.

from A Shot in the Dark  By Harris L. Coulter, Barbara Loe Fisher "Today, the whole-cell vaccine is made in essentially the same way as in the time of Bordet and Gengou, although each manufacturer prepares it differently, and the exact formula is considered a trade secret."

http://www.henkebartram.com/articles/Qualifying-for-Trade-Secret-Protection.pdf Qualifying for Trade Secret Protection The case of Merck & Co., Inc. v. Smithkline Beecham Pharmaceuticals gives an example. The plaintiff claimed trade secret protection for a process it developed for the production of a vaccine. The defendant claimed that the process was not a trade secret because its aspects were readily ascertainable in publications. The court rejected the defendant’s argument, stating that “[T]he choice of individually known components and techniques to create a working manufacturing process is often, as here, a difficult undertaking. Where at individual steps of a process there are a variety of alternatives, the choice made through much effort of specific ingredients, materials, conditions and steps in an actual, working process constitutes a trade secret.”

http://www.ehponline.org/docs/2008/116-10/EHP116pa418PDF.PDF Because the actual levels of thimerosal used in each vaccine are a trade secret, we were not able to directly control for possible exposure to thimerosal in our analysis.

http://www.ibiblio.org/pub/archives/whitehouse-papers/1993/Apr/Immunization-Fact-Sheet-4193 Universal Vaccine Purchase and Provision The bill would require that the Secretary consult with other Federal agencies for advice on the quantities of recommended childhood vaccine to be purchased.  It would authorize the Secretary to consult with representatives of State governments, experts in vaccine delivery, health care providers, and other experts prior to commencing negotiations for the purchase of vaccine.  This proposal would direct the Secretary to negotiate a reasonable price with manufacturers participating in a procurement.  The price would be based on data supplied to the Secretary by manufacturers regarding (1) costs related to research and development, production, distribution to States and health care providers, and marketing; (2) profit levels sufficient to encourage future investment in research and development; and (3) the ability to maintain adequate outbreak control.  In addition, the bill would require that data provided to the Secretary be treated as a trade secret or confidential information for purposes of the Freedom of Information Act and would provide criminal sanctions for violations of this provision.

http://www.leg.state.fl.us/data/session/2005/Senate/bills/billtext/pdf/s2034.pdf A bill to be entitled 2 An act relating to public records exemptions; 3 creating s. 288.961, F.S.; clarifying the 4 public records exemption relating to trade 5 secrets for proprietary confidential business 6 information owned or controlled by the 7 not-for-profit corporation operating the 8 Florida Vaccine Research Institute and its 9 subsidiaries; expanding the public records 10 exemption to include information received from 11 a person in this or another state or nation or 12 the Federal Government which is otherwise 13 exempt or confidential under the laws of this 14 or another state or nation or under federal 15 law; providing for future review and repeal; 16 providing a statement of public necessity; 17 providing an effective date.

http://www.ahrp.org/cgi-bin/perlfect/search/search.pl?q=infomails 8. Was Traci Johnson driven to suicide by anti-depressants? That's a trade secret, ... Was Traci Johnson driven to suicide by anti-depressants? That's a trade secret, say US officials Search Archives Preview New Site About AHRP / Mission Statement What's... URL: http://www.ahrp.org/infomail/05/06/19.php   Score: 18%   Date: -   Size: 19 kB

http://www.lex-electronica.org/docs/articles_71.pdf Intellectual Property Protection for Plant Derived Vaccine Technology: Here They Come Are we Ready or Not? Presently the most common source of IP protection sought for PDVs is a patent. PDVs may also be protected as trade secrets. Trade secret protection is not grounded in statute, but is rooted in business practices which protect confidentiality of information relating to an innovation.8 Trade secret protection relies upon confidentiality rather than registration and is understood to be an alternative to patent protection.9 Reliance upon confidentiality renders trade secret a fragile IP right, because the protection can be immediately and irretrievably lost upon disclosure. Nowadays, due to innovations which promote quick and wide-spread distribution of information, such as the internet, trade secret protection can literally be lost at the push of a button. The upside of trade secret protection is the competitive advantage that it can provide because, unlike patents, no public disclosure is required. In an environment where adequate confidentiality measures are in place and enforceable, trade secrets provide an effective means of concealing information from the public and thereby securing a market sector monopoly.10

http://www.uscfc.uscourts.gov/book/export/html/4044 (1) that is trade secret or commercial or financial in substance and is privileged or confidential; or

https://www.softwaretechnews.com/stn_view.php?stn_id=45&article_id=109 Introduction to U.S. Intellectual Property Law by Robert L. Vienneau, ITT Corporation and Milton Johns, ITT Corporation Trade secrets are defined in a slightly different way in each state, but the Uniform Trade Secrets Act, as amended in 1980 (hereafter “UTSA”), is a good point of departure for a general definition. Under the UTSA, “ ‘Trade secret’ means information, including a formula, pattern, compilation, program, device, method, technique, or process, that (i) derives independent economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use, and (ii) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy.”

http://www.vran.org/vaccines/vacing/vac-ing-can.htm People should also know that the manufacturers do not disclose all the ingredients nor full details of the manufacturing process. Health Canada protects the "proprietary rights" of these companies and upholds their right to secrecy - something the greater Canadian public should be up in arms about. That parents are expected to submit their children for injection with multiple vaccines without first having full disclosure of all known ingredients is a disturbing statement on the control exerted by monopoly medicine and corporate and government allies.

http://www.udaan.org/autism/vaccine_safety.html Strangely vaccine damaged children also have high levels of arsenic and lead in their bodies. Are these also a component of vaccines? Unless a full disclosure is made it is difficult to say what exactly vaccines are composed of.

http://www.khlaw.com/showpublication.aspx?Show=608 Labeling of GMO-Derived Food Ingredients: A Recipe for Misinformation The consumer’s need for accurate information is of paramount importance: no one here disputes this fact. What we all should remember, however, is that this need is not a mandate for selective inclusion of label information by individuals or groups that may support or oppose a given technology or ingredient. There is, rather, an ethical and moral imperative to provide full, accurate and non-misleading information that is of real value to consumers. The consumer has no right to misleading information and does not wish to be misled. A simple statement regarding the presence of genetically modified components, delivered out of context and without appropriate elaboration, fails this test entirely. Inaccurate and misleading information is worse than no information at all. For this reason this Committee should, indeed must, oppose any further efforts to mandate, endorse or agree to uninformative, inaccurate and incomplete labeling cloaked in the guise of full disclosure, until such time as it can establish meaningful criteria to ensure that consumers receive the whole story, and not just what one or another interested party would like them to know.

A northern state in Nigeria that is at the heart of a spreading polio outbreak said Sunday that it would not relent on its boycott of a mass vaccination program, which it has called a U.S. plot to spread AIDS and infertility among Muslims ....Kano state officials say their lab tests carried out late last year found estrogen and other female sex hormones in the polio vaccine -- proof, they say, that the vaccines are contaminated. [Media Feb 2004] Province at heart of outbreak alleges anti-Muslim plot The Associated Press obtained a copy of the committee's interim report that ruled the vaccines safe. However, it acknowledged the tests showed "trace amounts of estradiol," a form of the female hormone estrogen the vaccine's Muslim detractors claim could cause infertility. ...Muslims in Nigeria's north have been wary of vaccine campaigns since 1996, when families in Kano state accused New York-based Pfizer Inc. of using an experimental meningitis drug without fully informing of the risks.....The company denied any wrongdoing. A U.S. court dismissed a lawsuit by 20 disabled Nigerians who allegedly took part in the study, but a U.S. appeals court later revived it. Vaccine Boycott Grows in Northern Nigeria

So there ya go! Inactive ingredients, such as peanut oil in an adjuvant or vaccine carrier, does not have to appear on the label of a vaccine.

Popularity:   message viewed 5036 times
URL:   http://www.curezone.org/blogs/fm.asp?i=1338286

<< Return to the standard message view